Introduction: The incidence of ectopic pregnancy (EP) increased almost up to a level of 2% in developed countries. Using of transvaginal ultrasonography and sensitive plasma-human chorionic gonadotropin (β-HCG) has enabled an early diagnosis before rupture. Early diagnosis allows the full range of treatment options. So, emergency surgery has been changed to a more benign condition. Administration of methotrexate (MTX) has an acceptance in selected patients and is considered costly effective with no need for waiting period before attempting another pregnancy. Although methotrexate is a teratogenic agent, its half-life is very short. Aim of work: To evaluate the safety and efficacy of laparoscope versus MTX of well-selected cases of undisturbed ectopic pregnancy. Materials and Methods: This is a prospective study in Minia University Hospitals during the period from March 2015 to March 2016. Forty patients of undisturbed EPs were divided randomly into two groups (20 for each group), the first group included women undergoing laparoscopic salpingostomy and the second group included women undergoing MTX. Every participant was subjected to full history taking, general, abdominal and vaginal examinations, as well as β-HCG, abdominal and vaginal ultrasound scan investigations. Only with MTX group and according to Lipscomb 2012, MTX was administrated and assessed. After full range of treatment, a close weekly follow-up of all groups was done by β-HCG level as well as abdominal and vaginal examination and ultrasonography. Results: The mean pre-therapeutic level of β-HCG was 1081.9±655.85 mIU/ml in MTX group and 2180.75±1693.51 mIU/ml in laparoscopy group. As regarding the success rate, MTX group was 70% and not significantly different from laparoscopic 85%. Conclusion: Undisturbed EP can be treated effectively by MTX, especially in selected cases depending mainly on β-HCG low levels pre-therapeutic and follow-up.
INTRODUCTION
Extra uterine pregnancy can often be diagnosed before the patient's condition is deteriorated, so changed into a more benign condition. Diagnostic integrating transvaginal ultrasound and level of human chorionic gonadotrophin (hCG) measurement are the cornerstone of a timely diagnosis (Ankum et al., 1996) . Timely diagnosis allows us to consider the full range of treatment options. This is important not only in focused on immediate therapeutic management success (i.e. elimination of the EP) which is a narrow aim but also retaining optimal fertility for those women desiring future pregnancy (Hajenius et al., 2007) .
Nowdays, treatment options for EP patients are surgery, medical treatment or expectant management. In surgery, laparoscopy is now the accepted approach for making salpingostomy or salpingectomy. Administration of MTX has gained an acceptance in selected patients. Expectant management has been advocated based on the knowledge that the course of many early EP is a selflimiting process, ultimately resulting in tubal abortion or re-absorption. A well-recognized hazard after surgical line, systemic MTX treatment and expectant management is persistent trophoblast, abortion or re-absorption. Persistent trophoblast may lead to recurrence of clinical symptoms and is an indication for additional treatment. Serum β-HCG monitoring enables the timely detection of inadequately declining serum β-HCG concentrations after treatment (Hajenius et al.,2007) .
At the end, both randomized trial and prospective study found that the cost effectiveness of methotrexate treatment for women was quite substantial (Graczykowski JW and Mishell DR., 1997).
AIM OF WORK
To evaluate the safety and efficacy of laparoscopic versus medical management of well selected cases of undisturbed ectopic pregnancy. 
PATIENTS AND METHODS

Study design:
Consent:
All participants had signed a written informed consent after they have been made aware of the purpose of the study, interventions, outcome and possible complications. The researcher confirmed confidentiality of their information that will never be used for purposes other than scientific research.
Study sample: Forty patients of undisturbed EPs and after counseling, the women were randomized and divided into two groups (20 for each group), the first group (women undergoing to laparoscopic salpingostomy) and the second group (undergoing to MTX).
Study methods:
All studied patients were subjected to full history taking including complete medical and surgical history, general examination (pulse, temperature, blood pressure, weight and height). Abdominal and vaginal examinations, investigations (β-hCG, serum creatinine, liver function, Rh, and CBC). Ultrasound Scan (abdominal and vaginal) was also performed. Lastly and after full range of treatment, a close follow-up mainly by serum β-hCG level weekly, vital signs, abdominal and vaginal examination in addition to ultrasonography.
MTX administration and assessment: Only with
MTX group and according to Lipscomb 2012, day (0) obtained β-HCG level and sonar, day (1) obtained levels of the β-HCG, liver function, blood urea, and creatinine as well as administration of a single-dose of MTX 1 mg/ kg IM. Day (4) obtained β-HCG level (baseline level against which subsequent levels are measured). Day (7) obtained β-HCG and AST levels and perform a complete blood count. Successful treatment: If the β-HCG level has dropped 15% or more at day 7, obtains weekly β-HCG levels until they have reached the negative level, if failure occurs, surgical intervention was performed.
Participants (MTX group):
Inclusion criteria according to Lipscomb 2012, the patient must be hemodynamically stable, reliable, compliant, and able to return for follow-up care. The size of the gestation should not exceed 4cm at its greatest dimension. No evidence of tubal rupture or fetal cardiac activity (by ultrasonographic findings). The β-HCG level is less than 5000 mIU/Ml. The exclusion criteria include coexistent viable intrauterine pregnancy, renal, hepatic or haematological impairment, breast feeding or known hypersensitivity to methotrexate, immunodeficiency/ concurrent use of corticosteroids.
Outcome measures: β-HCG titre on day 4, 7 and weekly until it reached zero and HSG after 8 weeks.
Data management:
The collected data were analyzed by using the statistical package for social sciences software (SPSS-version19). Graphics were done by Excel Microsoft office 2010. Quantitative data were presented as means and standard deviations, while qualitative data were presented as frequency distribution and percentages. Standard t-tests or the MannWhitney U tests will be used for comparison between patients received systemic MTX and laparoscopy. The probability of less than 0.05 was used as a cut off point for all significant tests.
RESULTS
Forty patients of undisturbed ectopic pregnancy were divided into two groups, twenty cases received single dose of methotrexate (1 mg/kg im) and the remaining cases underwent laparoscopic salpingostomy. The mean pre-therapeutic β-HCG titre (miu/ml) of methotrexate group was (1081.9) and of laparoscopic group was (2180.75) and p. value was 0.006* 
DISCUSSION
Medical treatment by MTX in an outpatient setting is now a realistic option. This modality was introduced in 1991 by Stovall et al. (Stovall TG et al., 1992) . In 1997, the first randomized clinical trial on MTX against laparoscopic salpingostomy was published (Hajenius PJ et al., 2000) .
In our study, there were no significant differences between the two groups in the baseline characteristics ( Table 1 ).
The parameter considered most important for MTX treatment of unruptured EP is β-HCG. (Lipscomb et al., 1999 ) demonstrated its importance (Lipscomb et al., 1999) and shown that the higher the level of β-HCG, the lower the chances of successful treatment. Farquhar CM 2005 was compared with a single dose MTX (50 mg/m2) versus laparoscopic surgery and reported that one single dose of systemic methotrexate intramuscularly (50 mg/m2 or 1 mg/kg body weight) was significantly less successful than laparoscopic salpingostomy in the elimination of tubal ectopic pregnancy (OR 0.38, 95% CI 0.20 to 0.71). This was mainly the result from inadequately declining serum β-HCG concentrations for which additional methotrexate injections were given (OR 3.3, 95% CI 1.7 to 6.7). The difference in results as serum β-HCG was less than 10 000 IU/l, but in our study ( Table 2 ) the mean pre-therapeutic level of β-HCG was 1081.9 ± 655.85 mIU/ml in MTX group and 2180.75 ± 1693.51 mIU/ml in laparoscopy group. Erdem M et al., 2004 reported that the mean pre-treatment β-HCG level was significantly lower in patients who were successfully treated with MTX than in patients who failed MTX therapy (1,932 ± 2,361 mIU/ml vs. 6,955 ± 2,690 mIU/ml) respectively (p < 0.05).
As regards the success rate ( 
